Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Novo Nordisk Articles

Novo Nordisk Still Accepting Community Star Entries
Novo Nordisk and Two-Time Super Bowl Champion Kendall Simmons Kick-Off Search for Type 2 Diabetes Patients Who Give Back to Their Communities
He’s a Type 1 on TV and in Real Life
Brown, White and Beige: Not in Fashion But in Fat
Behind the Wheel, But Still in Control
Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs
Paula Deen: Cooking Up a New Life With Diabetes
Diabetes on the Rise in Saudi Arabia
Insulin degludec
FDA Says Levemir OK for Pregnant Women
Novo Nordisk Archives
Browse the Novo Nordisk Archives
Subscribe to the Community RSS Feed
Print | Email | Share | Comments (0)

Novo Nordisk Suspends Development of Insulin Sensitizer - Tumors Found in Animal Tests


Oct 1, 2002

Novo Nordisk has suspended development of ragaglitazar - a drug that has potential for regulating both blood-glucose and lipid levels-after finding urine bladder tumors in one mouse and several rats tested with the drug during preclinical trials.

Current clinical trials have been halted, and planned new clinical trials have been suspended, according to a news release from the company.

"The tumors observed may prove to be specific for the rodent species and in that case, they will be of no relevance to humans," says Mads Krogsgaard Thomsen, chief science officer of Novo Nordisk. "However, we have for patient safety reasons decided to take a precautionary approach and stop the ongoing clinical trials while we investigate the preclinical findings in more detail."

Thomsen says it is too early to tell whether new clinical trials will be initiated. If they are, Thomsen expects a delay of about two years.

Categories: Insulin, Medications Research, Novo Nordisk

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Oct 1, 2002

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.